GE

286.24

+1.58%↑

RTX

157.93

+1.24%↑

CAT

435.96

+1.13%↑

BA

215.78

-0.23%↓

GEV.US

627.87

+0.32%↑

GE

286.24

+1.58%↑

RTX

157.93

+1.24%↑

CAT

435.96

+1.13%↑

BA

215.78

-0.23%↓

GEV.US

627.87

+0.32%↑

GE

286.24

+1.58%↑

RTX

157.93

+1.24%↑

CAT

435.96

+1.13%↑

BA

215.78

-0.23%↓

GEV.US

627.87

+0.32%↑

GE

286.24

+1.58%↑

RTX

157.93

+1.24%↑

CAT

435.96

+1.13%↑

BA

215.78

-0.23%↓

GEV.US

627.87

+0.32%↑

GE

286.24

+1.58%↑

RTX

157.93

+1.24%↑

CAT

435.96

+1.13%↑

BA

215.78

-0.23%↓

GEV.US

627.87

+0.32%↑

Ocugen Inc

Отворен

1.19 12.26

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.15

Максимум

1.23

Ключови измерители

By Trading Economics

Приходи

611K

-15M

Продажби

-108K

1.4M

Марж на печалбата

-1,073.489

Служители

95

EBITDA

724K

-13M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+491.59% upside

Дивиденти

By Dow Jones

Следващи печалби

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.4M

322M

Предишно отваряне

-11.07

Предишно затваряне

1.19

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.09.2025 г., 22:41 ч. UTC

Значими двигатели на пазара

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12.09.2025 г., 16:04 ч. UTC

Значими двигатели на пазара

Upexi Shares Climb on Solana Gains

14.09.2025 г., 23:48 ч. UTC

Пазарно говорене

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14.09.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Lower on Likely Technical Correction -- Market Talk

14.09.2025 г., 23:38 ч. UTC

Пазарно говорене

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14.09.2025 г., 23:13 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.09.2025 г., 23:04 ч. UTC

Пазарно говорене

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13.09.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

12.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

12.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.09.2025 г., 20:09 ч. UTC

Печалби

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12.09.2025 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12.09.2025 г., 19:16 ч. UTC

Пазарно говорене

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12.09.2025 г., 19:03 ч. UTC

Пазарно говорене

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12.09.2025 г., 18:59 ч. UTC

Пазарно говорене

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12.09.2025 г., 18:38 ч. UTC

Пазарно говорене
Печалби

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12.09.2025 г., 18:33 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12.09.2025 г., 18:22 ч. UTC

Пазарно говорене

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12.09.2025 г., 16:56 ч. UTC

Пазарно говорене

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12.09.2025 г., 16:22 ч. UTC

Печалби

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.09.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

12.09.2025 г., 16:11 ч. UTC

Печалби

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12.09.2025 г., 15:37 ч. UTC

Пазарно говорене

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12.09.2025 г., 15:22 ч. UTC

Пазарно говорене

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12.09.2025 г., 15:07 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

491.59% нагоре

12-месечна прогноза

Среден 6.33 USD  491.59%

Висок 8 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat